Cytokinetics (CYTK) Looks Good: Stock Soars 16.1% – Tale of the Tape

January 2, 2015 Technicals 0

Zacks

Cytokinetics, Inc. (CYTK) was a big mover last session with its shares rising just over 16% on the day. The upside was a result of Roth Capital increasing its price target on the biotech company to $18 from $13 and reiterating its "buy" rating on the stock. This development led to far more shares changing hands yesterday than in a normal session. This continues the recent uptrend of the company as the stock has gained roughly 78% in the past one-month time frame.

The company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn’t been in trend either. Wednesday’s rally is encouraging though, so make sure to keep a close watch on this firm in the near future.

Cytokinetics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Investors interested in the biomedical industry may also consider Affymetrix Inc. (AFFX) that sports a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

Be the first to comment

Leave a Reply